REG - Intertek Group Plc - Acquisition

IntertekAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251103:nRSC7921Fa&default-theme=true

RNS Number : 7921F  Intertek Group PLC  03 November 2025

INTERTEK EXPANDS ATIC FOOTPRINT IN CENTRAL AMERICA WITH ACQUISITION OF LEADING COSTA RICAN TESTING BUSINESS SUPLILAB

 

•      Fast-growing Costa Rican economy is driving a strong demand for
Risk-based Quality Assurance services in food safety and medical device
testing sectors

 

•      Suplilab is a high-quality ATIC provider with a leading scale
position and a track record of fast growth in high-margin sectors

 

•      Acquisition of Suplilab gives Intertek immediate access to
attractive ATIC growth opportunities in Central America

 

More information is available here:
https://www.intertek.com/investors/suplilab-video/
(https://www.intertek.com/investors/suplilab-video/)

 

3 November 2025: Intertek Group plc ("Intertek" and "Group"), a leading Total
Quality Assurance provider to industries worldwide, is pleased to announce
that it has acquired Suplilab, a market-leading provider of food safety and
medical devices testing services, based in San José, Costa Rica.

 

The Costa Rican economy is growing rapidly, creating a significant market for
Risk-based Quality Assurance solutions that can cater to rising demand from
consumers for safer and more sustainable food options, and the strong
expansion of the country's medical devices market.

 

Suplilab is a high-quality business with industry-leading technical expertise
in microbiology, water and chemistry testing and has established a
market-leading position in the food and medical devices sectors based on a
strong track record of rapid growth in these high-margin spaces. Suplilab
employs 38 highly skilled colleagues and generated revenues of £3.1m in 2024.

 

The acquisition will enable Intertek to establish a leading position in Costa
Rica's food and medical devices sectors, offering immediate access to a large
customer base and a fast-growing ATIC market in Central America.

 

André Lacroix, Chief Executive Officer of Intertek, said: "The acquisition of
Suplilab in Costa Rica is an exciting opportunity to enter into Central
America's high-growth, high-margin food and medical devices spaces, deepening
our industry-leading ATIC footprint in Latin America. We look forward to
working with the Suplilab team to seize the exciting growth opportunities
ahead."

 

 

-ENDS-

 

 

For further information please contact:

 

Denis Moreau, Investor Relations

Telephone: +44 (0) 20 7396 3415
 investor@intertek.com (mailto:investor@intertek.com)

 

Jonathon Brill/James Styles, DGA

Telephone: +44 (0) 7836 622 683
intertek@dgagroup.com (mailto:intertek@dgagroup.com)

 

 

About Intertek

 

Intertek is a leading Total Quality Assurance provider to industries
worldwide.

 

Our network of more than 1,000 laboratories and offices in more than 100
countries, delivers innovative and bespoke Assurance, Testing, Inspection and
Certification solutions for our customers' operations and supply chains.
Intertek is a purpose-led company that brings Quality, Safety and
Sustainability to Life.

 

Our Science-based Customer Excellence USP and the 24/7 mission critical
Quality Assurance solutions we provide, ensure that our clients can operate
with well-functioning supply chains in each of their operations.

 

Our Customer Promise is: Intertek Total Quality Assurance expertise, delivered
consistently, with precision, pace and passion, enabling our customers to
power ahead safely.

 

intertek.com (http://www.intertek.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQEANFFESFSFFA



            Copyright 2019 Regulatory News Service, all rights reserved